Esmaeil Samadian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esmaeil Samadian has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ali Bidmeshkipour
Department of Cell and Molecular Biology, Faculty of Science, Razi University, Kermanshah, Iran
2 shared publicationsEhsan Soleymani-Nejadian
2 shared publications- Roghaye Gharaei
Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2 shared publications - Ashraf Aleyasin
Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication Atefeh Shirkavand
Department of Cell and Molecular Biology, Faculty of Science, Razi University, Kermanshah, Iran
1 shared publication- Ehsan Soleymaninejadian
Department of Clinical, Surgical, Diagnostics and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy
1 shared publication
Latest Publications
- 3 March 2022
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 39 (4) , 995-1008
Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome
Purpose Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women, is typically accompanied by a defective oxidative defense system. Here, we investigated the effect of astaxanthin (AST) as a powerful antioxidant on the oxidative stress (OS) response and assisted reproductive technology (ART) outcomes in PCOS patients. Methods In this double-blind, randomized, placebo-controlled trial, PCOS patients were randomly assigned into two groups. The intervention group received 8 mg AST, and the control group received the placebo daily for 40 days. The primary outcomes were the serum and follicular fluid (FF) levels of the OS biomarkers and the expression levels of the specific genes and proteins in the oxidative stress response pathway. The secondary outcomes were considered ART outcomes. Results According to our findings, a 40-day course of AST supplementation led to significantly higher levels of serum CAT and TAC in the AST group compared to the placebo group. However, there were no significant intergroup differences in the serum MDA and SOD levels, as well as the FF levels of OS markers. The expression of Nrf2, HO-1, and NQ-1 was significantly increased in the granulosa cells (GCs) of the AST group. Moreover, the MII oocyte and high-quality embryo rate were significantly increased in the AST group compared to the placebo group. We found no significant intergroup difference in the chemical and clinical pregnancy rates. Conclusion AST treatment has been shown to increase both serum TAC levels and activation of the Nrf2 axis in PCOS patients’ GCs. Trial Registration ClincialTrials.gov Identifier: NCT03991286.
- 3 March 2022
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 39 (4) , 995-1008
Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome
Purpose Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women, is typically accompanied by a defective oxidative defense system. Here, we investigated the effect of astaxanthin (AST) as a powerful antioxidant on the oxidative stress (OS) response and assisted reproductive technology (ART) outcomes in PCOS patients. Methods In this double-blind, randomized, placebo-controlled trial, PCOS patients were randomly assigned into two groups. The intervention group received 8 mg AST, and the control group received the placebo daily for 40 days. The primary outcomes were the serum and follicular fluid (FF) levels of the OS biomarkers and the expression levels of the specific genes and proteins in the oxidative stress response pathway. The secondary outcomes were considered ART outcomes. Results According to our findings, a 40-day course of AST supplementation led to significantly higher levels of serum CAT and TAC in the AST group compared to the placebo group. However, there were no significant intergroup differences in the serum MDA and SOD levels, as well as the FF levels of OS markers. The expression of Nrf2, HO-1, and NQ-1 was significantly increased in the granulosa cells (GCs) of the AST group. Moreover, the MII oocyte and high-quality embryo rate were significantly increased in the AST group compared to the placebo group. We found no significant intergroup difference in the chemical and clinical pregnancy rates. Conclusion AST treatment has been shown to increase both serum TAC levels and activation of the Nrf2 axis in PCOS patients’ GCs. Trial Registration ClincialTrials.gov Identifier: NCT03991286.
- Open Access
- 1 October 2013
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 14 (4) , 419-422
In Silico survey of functional coding variants in human AEG-1 gene
- 1 October 2013
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 14 (4) , 419-422
Open AccessIn Silico survey of functional coding variants in human AEG-1 gene
- Open Access
- 31 January 2013
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 14 (1) , 63-67
Lack of association between TRAF1/C5 rs10818488 polymorphism and rheumatoid arthritis in Iranian population
- 31 January 2013
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 14 (1) , 63-67
Open AccessLack of association between TRAF1/C5 rs10818488 polymorphism and rheumatoid arthritis in Iranian population
- 30 September 2011
- Published by Elsevier in Clinical Biochemistry
- Vol. 44 (13) , S277
Study of TRAF1/C5 intergenic region polymorphism-associated with rheumatoid arthritis in Kermanshah populations
- 30 September 2011
- Published by Elsevier in Clinical Biochemistry
- Vol. 44 (13) , S277
Study of TRAF1/C5 intergenic region polymorphism-associated with rheumatoid arthritis in Kermanshah populations
- 23 September 2011
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 67 (1) , 1-8
Immunomodulatory Properties of Mesenchymal Stem Cells: Cytokines and Factors
Citation Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012; 67: 1–8Mesenchymal stem cells (MSCs) are defined as undifferentiated cells that are capable of self renewal and differentiation into several cell types such as chondrocyte, adipocyte, osteocyte, myocyte, hepatocyte, and neuron‐like cells. MSC can be isolated from bone marrow, umbilical cord blood, adipose tissue, placenta, periosteum, trabecular bone, synovium, skeletal muscle, and deciduous teeth. Immunomodulatory of MSCs is one of the important issues nowadays, because this aspect can be clinically applied for graft‐versus‐host and autoimmune diseases. In this review, we tried to discuss in detail about cytokines and factors such as members of the transforming growth factor superfamily (transforming growth factor‐β), hepatic growth factors (HGF), prostaglandin E2 (PGE2), IL‐10, indolamine 2,3‐dioxygenase (IDO), nitric oxide (NO), heme oxygenase‐1 (HO‐1), and human leukocyte antigen‐G (HLA‐G) that are involved in immunomodulatory of MSCs.
- 23 September 2011
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 67 (1) , 1-8
Immunomodulatory Properties of Mesenchymal Stem Cells: Cytokines and Factors
Citation Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012; 67: 1–8Mesenchymal stem cells (MSCs) are defined as undifferentiated cells that are capable of self renewal and differentiation into several cell types such as chondrocyte, adipocyte, osteocyte, myocyte, hepatocyte, and neuron‐like cells. MSC can be isolated from bone marrow, umbilical cord blood, adipose tissue, placenta, periosteum, trabecular bone, synovium, skeletal muscle, and deciduous teeth. Immunomodulatory of MSCs is one of the important issues nowadays, because this aspect can be clinically applied for graft‐versus‐host and autoimmune diseases. In this review, we tried to discuss in detail about cytokines and factors such as members of the transforming growth factor superfamily (transforming growth factor‐β), hepatic growth factors (HGF), prostaglandin E2 (PGE2), IL‐10, indolamine 2,3‐dioxygenase (IDO), nitric oxide (NO), heme oxygenase‐1 (HO‐1), and human leukocyte antigen‐G (HLA‐G) that are involved in immunomodulatory of MSCs.